Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120731 | 0.90 | DPP4 (0.62) | DPP4ALDH1A1 | |
| SCHEMBL30411923 | 0.84 | ALDH1A1 (0.47) | DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL2746323 | 0.82 | DPP4 (0.58) | DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL4120711 | 0.78 | DPP4 (0.72) | DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL14679309 | 0.77 | CHRNB2 (0.33) | DPP4 | |
| SCHEMBL4324459 | 0.76 | CA12 (0.32) | DPP4ALDH1A1MAPT | |
| SCHEMBL5515622 | 0.75 | MLYCD (0.30) | DPP4 | |
| SCHEMBL4121228 | 0.75 | DPP4 (0.62) | DPP4 | |
| SCHEMBL14197152 | 0.70 | MLYCD (0.38) | ALDH1A1MAPT | |
| SCHEMBL5103035 | 0.70 | DPP4 (0.53) | DPP4ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | DPP4 2434/4885ALDH1A1 3505/4885MAPT 2374/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | DPP4 3743/4885ALDH1A1 4132/4885MAPT 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.